Depends on the blinded data. If the median OS from the blinded data comes in at >=22 months, I think that will and could be a game changer. I actually think it will come in close to 24 months.
Anything above 22 months will attract the eye of wall street investors, and that in a self could be huge. With KITE & JUNO already cashing in on the Immunotherapy excitement, and with this being soooooo undersold, (even with the diluted shares), it could easily push this over $1.
With 450 Million shares (assuming all warrants, all shares, everything), a $10B market cap (where KITE & JUNO were bought out at), gives a share price of $4